ConductScience.org, home

Paper39459028

Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications.

Debnath SK and 4 others. Pharmaceuticals (Basel), 2024. Cited by 33 papers, by iCite.

Cite this record

ConductScience Library. Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications. Papers, record 39459028. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39459028

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications.
PubMed
Journal
Pharmaceuticals (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
33
iCite
Relative citation ratio, by iCite
5.79, provisional
iCite
Revised in PubMed
2024-10-28
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Debnath SKSujit Kumarhttps://orcid.org/0000-0002-9480-7686
2Debnath MMonalishahttps://orcid.org/0000-0002-9515-8307
3Ghosh AArnab
4Srivastava RRohithttps://orcid.org/0000-0002-3937-5139
5Omri AAbdelwahabhttps://orcid.org/0000-0002-4093-5762

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References79

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126848553Perfluorocarbon-Loaded Hollow Bi2Se3 Nanoparticles for Timely Supply of Oxygen under Near-Infrared Light to Enhance the Radiotherapy of Cancer.Adv Mater2016https://conductscience.org/library/papers/26848553PubMed
234191525Reversing Hypoxia with PLGA-Encapsulated Manganese Dioxide Nanoparticles Improves Natural Killer Cell Response to Tumor Spheroids.Mol Pharm2021https://conductscience.org/library/papers/34191525PubMed
325581937Hypoxia-inducible factor-1 and associated upstream and downstream proteins in the pathophysiology and management of glioblastoma.Neurosurg Focus2014https://conductscience.org/library/papers/25581937PubMed
427768978TaOx decorated perfluorocarbon nanodroplets as oxygen reservoirs to overcome tumor hypoxia and enhance cancer radiotherapy.Biomaterials2017https://conductscience.org/library/papers/27768978PubMed
532316260Hypoxia-Driven Immune Escape in the Tumor Microenvironment.Cells2020https://conductscience.org/library/papers/32316260PubMed
633802292Advanced Imaging Techniques for Radiotherapy Planning of Gliomas.Cancers (Basel)2021https://conductscience.org/library/papers/33802292PubMed
736545470Anticarcinogenic potentials of tea catechins.Front Nutr2022https://conductscience.org/library/papers/36545470PubMed
834439338Glucose Transporters as a Target for Anticancer Therapy.Cancers (Basel)2021https://conductscience.org/library/papers/34439338PubMed
934525344Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer.Cell Chem Biol2022https://conductscience.org/library/papers/34525344PubMed
1034628029Hypoxia signaling: Challenges and opportunities for cancer therapy.Semin Cancer Biol2022https://conductscience.org/library/papers/34628029PubMed
1134476218Vascular Normalization: A New Window Opened for Cancer Therapies.Front Oncol2021https://conductscience.org/library/papers/34476218PubMed
1233106581Hypoxia and its therapeutic possibilities in paediatric cancers.Br J Cancer2021https://conductscience.org/library/papers/33106581PubMed
1338346140Tumor-targeting bacteria as immune stimulants - the future of cancer immunotherapy?Crit Rev Microbiol2024https://conductscience.org/library/papers/38346140PubMed
1433059825Imaging of Tumor Hypoxia for Radiotherapy: Current Status and Future Directions.Semin Nucl Med2020https://conductscience.org/library/papers/33059825PubMed
1532974385Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance.Front Mol Biosci2020https://conductscience.org/library/papers/32974385PubMed
1636968288Tumor microenvironment in glioblastoma: Current and emerging concepts.Neurooncol Adv2023https://conductscience.org/library/papers/36968288PubMed
1733401572Flavonoids Targeting HIF-1: Implications on Cancer Metabolism.Cancers (Basel)2021https://conductscience.org/library/papers/33401572PubMed
1834665844PKI-587 enhances radiosensitization of hepatocellular carcinoma by inhibiting the PI3K/AKT/mTOR pathways and DNA damage repair.PLoS One2021https://conductscience.org/library/papers/34665844PubMed
1933173809Targeted Nanotherapeutics for Respiratory Diseases: Cancer, Fibrosis, and Coronavirus.Adv Ther (Weinh)2021https://conductscience.org/library/papers/33173809PubMed
2030837280Artificial Oxygen Carriers-Past, Present, and Future-a Review of the Most Innovative and Clinically Relevant Concepts.J Pharmacol Exp Ther2019https://conductscience.org/library/papers/30837280PubMed

See all 79 referencesDownload CSV of references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 33 citations.

PMIDTitleJournalYearIn PapersSource
42930087Hypoxia-Responsive Fluorescent Prodrugs: Self-Reporting Drug Delivery or Activation in Living Systems.Biosensors (Basel)2026https://conductscience.org/library/papers/42930087PubMed
42841004Multifunctional Cu2-xSe nanomaterials for cancer theranostics: recent advances, therapeutic mechanisms, and translational challenges.Front Chem2026https://conductscience.org/library/papers/42841004PubMed
42793219Hypoxia-Targeting Strategies in Radiotherapy and Nitroimidazole-Based Radiosensitizers: A Narrative Review and Translational Perspectives.Curr Issues Mol Biol2026https://conductscience.org/library/papers/42793219PubMed
42455224Artificial Blood and Stem Cell-Derived Oxygen Therapeutics in Oncology: Emerging Strategies for Overcoming Tumor Hypoxia.Stem Cell Rev Rep2026https://conductscience.org/library/papers/42455224PubMed
42440727Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics.Front Oncol2026https://conductscience.org/library/papers/42440727PubMed
42274568Sulforaphane Enhances Cytotoxic Effects of Non-Thermal Plasma and Tirapazamine Combination Therapy in Pancreatic Adenocarcinoma Cells.Cells2026https://conductscience.org/library/papers/42274568PubMed
41723762Nervous and immune system crosstalk shapes cancer progression and treatment response.Discov Oncol2026https://conductscience.org/library/papers/41723762PubMed
41677522Nanomaterial-Enabled Modulation of Tumor-Associated Macrophages and Dendritic Cells to Enhance Cancer Immunotherapy.Nanomaterials (Basel)2026https://conductscience.org/library/papers/41677522PubMed
41625776Recent advances in lipid nanoparticles for cancer vaccine delivery: Challenges and future perspectives.Int J Pharm X2026https://conductscience.org/library/papers/41625776PubMed
41521160Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites.Cancer Med2026https://conductscience.org/library/papers/41521160PubMed
41516303Lanthanide Nanotheranostics in Radiotherapy.Int J Mol Sci2025https://conductscience.org/library/papers/41516303PubMed
41516128Hybrid Nanocarriers for Cancer Therapy: Advancements in Co-Delivery of Gene Therapy and Immunotherapy.Int J Mol Sci2025https://conductscience.org/library/papers/41516128PubMed
41514600Nanomedicine in Ovarian Cancer: Advances in Imaging, Targeted Delivery, and Theranostic Therapeutic Platforms.Cancers (Basel)2025https://conductscience.org/library/papers/41514600PubMed
41424453Progress in the Application of Nanobiotechnology in the Ablation Therapy of Hepatic Carcinoma.Int J Nanomedicine2025https://conductscience.org/library/papers/41424453PubMed
41409250Deciphering molecular pathways driving cancer invasion and metastasis: advances and therapeutic prospects.Front Oncol2025https://conductscience.org/library/papers/41409250PubMed
41089309Emerging strategies in radiation therapy: promises and challenges of spatial fractionation, ultra-high dose rates, and nanoparticles.J Phys D Appl Phys2025https://conductscience.org/library/papers/41089309PubMed
40963621Hypoxia and activation of hypoxia inducible factor alpha as influencers of inflammatory helper T cells in autoimmune disease - a link between cancer and autoimmunity.Front Immunol2025https://conductscience.org/library/papers/40963621PubMed
40943387Computational Discovery of Selective Carbonic Anhydrase IX (CA IX) Inhibitors via Pharmacophore Modeling and Molecular Simulations for Cancer Therapy.Int J Mol Sci2025https://conductscience.org/library/papers/40943387PubMed
40867257Nanoparticle-Based Delivery Strategies for Combating Drug Resistance in Cancer Therapeutics.Cancers (Basel)2025https://conductscience.org/library/papers/40867257PubMed
40486631Oxygen gradients in tumor tissues implications for breast cancer metastasis - a narrative review.Ann Med Surg (Lond)2025https://conductscience.org/library/papers/40486631PubMed

See all 26 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39459028

GET https://conductscience.org/api/papers/v1/39459028/references?page=2